Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00JWA
|
||||
| Former ID |
DNC010621
|
||||
| Drug Name |
N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [530694] | ||
| Formula |
C16H13N3O2
|
||||
| Canonical SMILES |
CC(=O)NC1=NC(=C(C=C1)C2=CC=NC=C2)C3=CC=CO3
|
||||
| InChI |
1S/C16H13N3O2/c1-11(20)18-15-5-4-13(12-6-8-17-9-7-12)16(19-15)14-3-2-10-21-14/h2-10H,1H3,(H,18,19,20)
|
||||
| InChIKey |
STFZQXRQDWXSGW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [530694] | |
| Adenosine A2b receptor | Target Info | Inhibitor | [530694] | ||
| Adenosine A2a receptor | Target Info | Inhibitor | [530694] | ||
| Adenosine A3 receptor | Target Info | Inhibitor | [530694] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.